Argenica Therapeutics (ASX:AGN) Total Stockholders Equity : A$6.59 Mil (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Argenica Therapeutics Total Stockholders Equity?

Argenica Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was A$6.59 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Argenica Therapeutics's Book Value per Share for the quarter that ended in Dec. 2023 was A$0.07. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Argenica Therapeutics's Debt-to-Equity for the quarter that ended in Dec. 2023 was 0.00.

Argenica Therapeutics Total Stockholders Equity Historical Data

The historical data trend for Argenica Therapeutics's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Argenica Therapeutics Total Stockholders Equity Chart

Argenica Therapeutics Annual Data

Trend

Jun21

Jun22

Jun23

Total Stockholders Equity

6.85

8.31

7.67

Argenica Therapeutics Semi-Annual Data
	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Total Stockholders Equity	Get a 7-Day Free Trial			5.33	8.31	6.95	7.67	6.59

Argenica Therapeutics (ASX:AGN) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Argenica Therapeutics's Book Value per Share for the quarter that ended in Dec. 2023 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(6.594	-	0)	/	99.1508
	=	0.07

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Argenica Therapeutics's Debt-to-Equity for the quarter that ended in Dec. 2023 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	6.594
	=	0.00

Argenica Therapeutics Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Argenica Therapeutics's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Argenica Therapeutics (ASX:AGN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Argenica Therapeutics Ltd (ASX:AGN) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

117 Broadway, Unit 4, Nedlands, WA, AUS, 6009

Website

https://www.argenica.com.au

Argenica Therapeutics Ltd is engaged in the development and commercialization of novel drug candidates. Its ARG007 drug improves outcomes in pre-clinical stroke models and is in the process of being verified for its safety and toxicology before commencing Phase 1 clinical trials in humans.

Argenica Therapeutics (ASX:AGN) Headlines

No Headlines